Inovio Pharmaceuticals Inc (NASDAQ:INO) – Analysts at Piper Jaffray Companies issued their Q1 2020 earnings estimates for shares of Inovio Pharmaceuticals in a research note issued to investors on Tuesday, March 12th. Piper Jaffray Companies analyst C. Raymond forecasts that the biopharmaceutical company will post earnings per share of ($0.31) for the quarter. Piper Jaffray Companies also issued estimates for Inovio Pharmaceuticals’ Q2 2020 earnings at ($0.31) EPS, Q3 2020 earnings at ($0.31) EPS and Q4 2020 earnings at ($0.29) EPS.
Inovio Pharmaceuticals (NASDAQ:INO) last released its earnings results on Tuesday, March 12th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.31) by ($0.03). Inovio Pharmaceuticals had a negative net margin of 318.11% and a negative return on equity of 88.61%. The company had revenue of $2.50 million for the quarter, compared to the consensus estimate of $2.69 million. During the same period in the prior year, the company earned ($0.23) earnings per share.
Other research analysts also recently issued reports about the stock. HC Wainwright set a $13.00 target price on shares of Inovio Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, January 16th. Zacks Investment Research raised shares of Inovio Pharmaceuticals from a “hold” rating to a “buy” rating and set a $5.25 price objective for the company in a report on Wednesday, January 16th. Maxim Group reaffirmed a “buy” rating and issued a $8.00 price objective on shares of Inovio Pharmaceuticals in a report on Tuesday, January 15th. Finally, ValuEngine raised shares of Inovio Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Wednesday, November 21st. One research analyst has rated the stock with a sell rating and six have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $9.65.
Inovio Pharmaceuticals stock opened at $3.62 on Thursday. Inovio Pharmaceuticals has a twelve month low of $3.02 and a twelve month high of $6.30. The company has a market cap of $348.03 million, a PE ratio of -3.45 and a beta of 1.72.
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Quantamental Technologies LLC bought a new position in Inovio Pharmaceuticals in the 4th quarter worth approximately $43,000. Amalgamated Bank bought a new position in Inovio Pharmaceuticals in the 4th quarter worth approximately $50,000. Pembroke Management LTD bought a new position in Inovio Pharmaceuticals in the 4th quarter worth approximately $52,000. Fox Run Management L.L.C. bought a new position in Inovio Pharmaceuticals in the 4th quarter worth approximately $58,000. Finally, Meeder Asset Management Inc. boosted its holdings in Inovio Pharmaceuticals by 522.6% in the 4th quarter. Meeder Asset Management Inc. now owns 14,718 shares of the biopharmaceutical company’s stock worth $59,000 after buying an additional 12,354 shares during the period. 37.31% of the stock is owned by institutional investors.
Inovio Pharmaceuticals Company Profile
Inovio Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops active DNA immunotherapies and vaccines to prevent and treat cancers and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune system's tolerance of cancerous cells, as well as is intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza.
See Also: What is the Dividend Aristocrat Index?
Receive News & Ratings for Inovio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.